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Summary
Background: Amiodarone is recognized as the most effective therapy for maintaining sinus
rhythm (SR) post cardioversion in patients with atrial ﬁbrillation (AF). It is also recommended
for controlling AF in patients with congestive heart failure (CHF). We retrospectively examined
the efﬁcacy and safety of oral amiodarone in patients with AF and CHF.
Methods: Forty-eight consecutive AF patients whose left ventricular ejection fraction (LVEF) was
less than 50% and B-type natriuretic peptide (BNP) was higher than 100 pg/ml were investigated
retrospectively, and divided into 3 groups: paroxysmal AF, 16 patients; persistent AF, 9 patients;
and permanent AF, 23 patients.
Results: The permanent AF group had a longer history of AF, larger left ventricular end-diastolic
diameter (LVDd) and left atrial diameter (LAD) than paroxysmal and persistent AF groups
(p < 0.05). After median follow-up of 265 days, amiodarone suppressed paroxysms in 88% of
paroxysmal AF patients, while SR was maintained in all persistent AF patients, and 35% of
permanent AF patients. Of the 32 persistent and permanent AF patients, 12 (71%) out of 17
maintained SR after successful electrical cardioversion, and conversion to SR occurred sponta-
neously in 5 (33%) out of 15. The effective group had signiﬁcantly smaller LVDd and LAD than
the ineffective group. In the effective group, BNP decreased signiﬁcantly from 723± 566 pg/ml
to 248± 252 pg/ml, (p < 0.0005) and LVEF increased signiﬁcantly from 33± 7% to 50± 13%
(p < 0.0005) during follow up, while no changes were observed in the ineffective group. The
patients with low LVEF (≤30%) beneﬁted comparably from amiodarone to the patients with LVEF
>30%. Complications occurred in 24 (50%) patients leading to discontinuation of amiodarone in
11 (23%).
∗ Corresponding author. Tel.: +81 358035231; fax: +81 358030131.
E-mail address:mihoko kawabata.cvm@tmd.ac.jp (M. Kawabata).
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Introduction
Effective rhythm control of atrial ﬁbrillation (AF) frequently
bestows clinically meaningful advantages, such as increased
exercise tolerance, improvement in symptoms, and preven-
tion of atrial remodeling. The incidence of AF increases with
the onset of congestive heart failure (CHF) and rhythm con-
trol is attempted in patients with AF and CHF in practice
[1,2].
Amiodarone is recognized as the most effective ther-
apy for maintaining sinus rhythm (SR) post cardioversion.
It is also recommended for controlling AF in patients with
CHF since it has little negative inotropic action and possibly
fewer proarrhythmic effects [3].
There are many reports about the effects of amiodarone
in AF patients with CHF from western countries [4—17], indi-
cating that it is effective in restoration and maintenance of
SR in those patients. However, there are few reports from
Japan [18]. The principal purpose of this retrospective study
was to evaluate the efﬁcacy and safety of oral amiodarone
in Japanese patients with AF and CHF for clinical use, which
would be meaningful in their management.
Methods
This study retrospectively investigated a total of 48 con-
secutive AF patients (39 men and 9 women, mean age
66± 10 years) treated with oral amiodarone between Jan-
uary 2004 and December 2008. All patients had symptomatic
CHF [New York Heart Association (NYHA) functional classes
II—IV] and their B-type natriuretic peptide (BNP) was higher
than 100 pg/ml. All patients had underlying heart disease
with an impaired left ventricular ejection fraction (LVEF)
less than 50% on echocardiography.
Inpatients underwent continuous electrocardiographic
(ECG) monitoring. At the outpatient clinic follow-up was
performed at least every 3 months. ECGs and a 24-h Holter
ECG were recorded regularly or when patients complained of
palpitation or other typical clinical symptoms. The efﬁcacy
of amiodarone therapy was assessed by using ECG, Holter
monitoring, or the recording of a pacemaker. In order to
assess adverse effects of amiodarone, spirometry, chest X-
ray, KL-6 level, thyroid hormones, and liver function were
checked. We checked clinical and demographic data, includ-
ing past medical history and prior medication, from medical
records. Follow-up was terminated in April 2009.
DeﬁnitionsWe recognized three categories: (1) Paroxysmal AF, deﬁned
as recurrent, self-terminating episodes of AF usually last-
ing <48 h, alternating with periods of SR; (2) Persistent AF,
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lped restore SR in paroxysmal and persistent AF patients with
ol by amiodarone resulted in the improvement of LV function
ology. Published by Elsevier Ltd. All rights reserved.
eﬁned as episodes of sustained AF that did not convert to
R spontaneously, but required pharmacological or electrical
ardioversion; (3) Permanent AF, deﬁned as continuous AF,
n which cardioversion had not been attempted or had been
nsuccessful, and in which AF was accepted as the long-term
hythm for that patient [3].
Treatment was considered effective when the dura-
ion and frequency of episodes of AF were suppressed
n paroxysmal AF, or when SR was maintained in per-
istent and permanent AF. The recurrence of AF was
eﬁned as any recording of AF on an ECG or 24-h Holter
onitoring.
tatistical methods
ll data are expressed as mean± SD or numbers and per-
entages of patients. Data were censored if the patient
iscontinued amiodarone, reached the end of the follow-
p period (April 2009), or was lost to follow-up. Differences
n continuous variables were analyzed with unpaired Stu-
ent’s t-test or ANOVA and Tukey post-hoc tests. The G-test
as used to test for independence in contingency tables.
value of p < 0.05 was considered statistically signiﬁcant.
he survival curve illustrating freedom from recurrence of
F and the curve for spontaneous conversion were assessed
y the Kaplan—Meier method. SPSS version 11.0.1 was used
or all statistical analyses.
esults
here were 16 patients in the paroxysmal AF group, 9 in
he persistent AF group, and 23 in the permanent AF group.
he median follow-up duration was 265 days (range 7—1920,
verage 378 days). Amiodarone was started after effective
nticoagulation therapy in all patients. The mean dose of
miodarone was 163± 80mg/day (range 50—400mg/day).
wenty-three patients discontinued amiodarone because of
lack of efﬁcacy or adverse effects. The underlying heart
iseases included ischemic heart disease 18, hypertensive
eart disease 10, valvular disease 7, idiopathic dilated
ardiomyopathy 5, tachycardia-induced cardiomyopathy 4,
ongenital heart disease 2, arrhythmogenic right ventricular
ardiomyopathy (ARVC) 1, and sarcoidosis 1.
The baseline characteristics of the patients are shown
n Table 1. The three AF groups differed in age (p < 0.05),
uration of history of AF (p < 0.05), left ventricular end-
iastolic diameter (LVDd; p < 0.005), and left atrial diameter
LAD; p < 0.05). In post-hoc comparisons, the mean age of
he paroxysmal AF group was signiﬁcantly higher compared
ith the other 2 groups. The permanent AF group had a sig-
iﬁcantly longer duration of AF and larger left atrium and
entricle compared with the other 2 groups.
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aFigure 1 Tree diagram showing results of tre
Tallying the results for patients who had never received
ardioversion, amiodarone suppressed AF in 14/16 of the
aroxysmal AF patients (88%), and caused spontaneous
eversion to SR in 4/4 persistent AF patients (100%), and
/11 permanent AF patients (9%) (Fig. 1). This translated to
he spontaneous achievement of SR in 5/15 non-paroxysmal
F patients (33%) without cardioversion after a median
ollow-up of 151 days. The time to attainment of SR
as within 4 months (mean 40 days) (Fig. 2). Meanwhile,
7 patients (5 in the persistent and 12 in the perma-
ent AF group) received electrical cardioversion. AF did
ot recur in any of the 5 persistent AF patients (100%),
nd 7/12 permanent AF patients (58%), translating to SR
aintenance in 12/17 (71%) patients receiving cardiover-
ion with a median follow-up of 216 days. Recurrence of
F among treatment failures was within 1 month with a
edian length of 16 days (Fig. 2). In total, amiodarone
as effective in 100% and 35% of the persistent and per-
anent AF patients, respectively. Among 14 patients who
ad previously failed to cardiovert with other antiarrhyth-
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igure 2 Left panel shows the Kaplan—Meier analysis of spontaneo
n non-paroxysmal atrial ﬁbrillation (AF) patients. Right panel show
fter cardioversion in non-paroxysmal AF patients.nt with oral amiodarone. AF, atrial ﬁbrillation.
ic agents (range, 1—7 agents), amiodarone was effective
n 9.
In the ineffective group (n = 17), LVDd and LAD were sig-
iﬁcantly longer compared with the effective group (n = 31)
Table 2). The BNP level was signiﬁcantly higher in the
ffective group. There was no signiﬁcant difference in
he maintenance dose of amiodarone between the groups.
hese results were the same in the non-paroxysmal patients
n = 32). LVDd and LAD were signiﬁcantly longer in the inef-
ective group (n = 15) compared with the effective group
n = 17) (LVDd 67± 9mm vs. 56± 10mm; p < 0.005; LAD
3± 7mm vs. 44± 7mm; p < 0.005). There were no signif-
cant differences in the age, gender, duration of AF, or the
aintenance dose of amiodarone between the groups.
In the amiodarone-effective group, BNP decreased signif-
cantly from 723± 566 pg/ml to 248± 252 pg/ml (p < 0.0005)
nd LVEF increased signiﬁcantly from 33± 7% to 50± 13%
p < 0.0005) during the follow-up period, while no changes
ere observed in the ineffective group. There were no
hanges in LVDd or LAD during the observation period in
us conversion to sinus rhythm after treatment with amiodarone
s the event-free Kaplan—Meier curve with no recurrence of AF
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Table 1 Baseline characteristics of the patients.
Paroxysmal (n = 16) Persistent (n = 9) Permanent (n = 23) Signiﬁcance*
Age (years) 71± 6** 61± 14 65± 9 p = 0.047
Male (%) 69 78 91 N.S.
Duration of AF (days) 941± 1610 96± 238 3068± 3994a p = 0.021
NYHA class (II/III/IV) 9/6/1 7/2/0 20/3/0 N.S.
BNP(pg/ml) 928± 899 733± 483 499± 386 N.S.
LVEF (%) 36± 9 34± 6 35± 7 N.S.
LVDd (mm) 53± 9 53± 10 65± 9a p = 0.004
LAD (mm) 41± 7 42± 5 51± 8a p = 0.009
Previous drug failures (%) 50 11b 22 p = 0.0012
Ablation (isthmus) (%) 0 11 9 N.S.
Medication
Beta-blockers (%) 44 56 74 p = 0.10
ACEi/ARB (%) 50 56 70 N.S.
Digitalis (%) 25 22 17 N.S.
Verapamil (%) 50 22 26 N.S.
Other antiarrhythmic agents (%) 13 11 13 N.S.
Statins (%) 19 22 17 N.S.
Hypertension (%) 56 56 74 N.S.
Diabetes mellitus (%) 44 33 35 N.S.
± Values are mean± SD.
ACEi, angiotensin-converting enzyme inhibitor; AF, atrial ﬁbrillation; ARB, angiotensin II receptor blocker; BNP, B-type natriuretic peptide;
LAD, left atrial diameter; LVDd, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart
Association; PVI, pulmonary vein isolation.
* p values≤ 0.1 are given, although signiﬁcance was deﬁned at the 0.05 level.
** Statistically signiﬁcant difference vs. both persistent and permanent atrial ﬁbrillation.
a vs. both paroxysmal and persistent atrial ﬁbrillation.
b vs. both paroxysmal and permanent atrial ﬁbrillation.
Table 2 Clinical characteristics of effective and ineffective patients.
Effective (n = 31) Ineffective (n = 17) p value
Age (years) 65± 11 67± 7 N.S.
Male (%) 75 94 0.092
Duration of AF (days) 581± 756 3470± 4877 0.055
BNP (pg/ml) 806± 725 468± 354 0.036
NYHA class (II/III/IV) 22/8/1 14/3/0 N.S.
LVEF (%) 34± 7 36± 9 N.S.
LVDd (mm) 55± 10 65± 11 0.002
LAD (mm) 43± 7 53± 7 0.001
Previous drug failures (%) 29 29 N.S.
Ablation (isthmus) (%) 10 0 N.S.
Dose of amiodarone (mg) 148± 52 188± 112 N.S.
Follow-up duration (days) 393± 349 350± 490 N.S.
Medication
Beta-blockers (%) 61 59 N.S.
ACEi/ARB (%) 61 59 N.S.
Digitalis (%) 23 18 N.S.
Verapamil (%) 35 29 N.S.
Other antiarrhythmic agents (%) 13 12 N.S.
Statins (%) 23 12 N.S.
Hypertension (%) 58 76 N.S.
Diabetes mellitus (%) 39 35 N.S.
ACEi, angiotensin-converting enzyme inhibitor; AF, atrial ﬁbrillation; ARB, angiotensin II receptor blocker; BNP, B-type natriuretic peptide;
LAD, left atrial diameter; LVDd, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart
Association.
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Figure 3 Effects of amiodarone treatment on clinical indices grouped by success or failure of rhythm control. Left side points show
pre-treatment values in individual patients, and the right side shows values after treatment. Amiodarone signiﬁcantly improved
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NP, B-type natriuretic peptide; EF, left ventricular ejection fra
iameter.
ither group (Fig. 3). During the follow-up period, 5 patients
ere admitted because of exacerbation of CHF. They con-
isted of 1 persistent and 4 permanent AF patients. There
as no signiﬁcant difference in the ratio of admission due to
eterioration of CHF between the amiodarone-effective and
ineffective groups (2/31, 6% vs. 3/17, 18%). One paroxysmal
F patient with ARVC started amiodarone during the hospi-
alization because of deteriorated CHF. Although the attacks
f AF were suppressed, CHF progressed and she died.
There were 16 patients with low LVEF (≤30%); 7 patients
n paroxysmal AF, 5 patients in persistent AF, and 4 patients
n permanent AF (p = 0.73). There were no signiﬁcant dif-
erences in the BNP levels, LVDd, or LAD between the
atients with LVEF ≤30% and those with LVEF >30% (BNP
47± 775 pg/ml vs. 606± 550 pg/ml; LVDd 60± 9mm vs.
8± 12mm; LAD 44± 7mm vs. 47± 9mm). Amiodarone was
ffective in 11/16 LVEF ≤30% group, and in 20/32 LVEF >30%
roup (p = 0.46).
m
l
m
daseline in the effective group, but not in the ineffective group.
; LVDd, left ventricular end-diastolic diameter; LAD, left atrial
Over the course of the follow-up period, adverse effects
ccurred in 24 (50%) patients. Recorded adverse effects
ere bradycardia in 7 (15%), thyroid dysfunction (all
ypothyroidism) in 10 (21%), pulmonary events in 8 (17%),
xcessive QT prolongation (QTc > 0.52) in 3 (6%), and liver
ysfunction in 1 (2%). Amiodarone was discontinued in 11
23%) of these patients (thyroid dysfunction 3, pulmonary
vents 7, and liver dysfunction 1). In the remaining 13,
miodarone dosage was decreased, or treatment for thyroid
ysfunction was initiated. Among 7 patients who showed
radycardia, 5 had sinus bradycardia of 40—60 BPM and in
he other 2 patients sick sinus syndrome was revealed and
acemakers were implanted. The most common non-cardiac
dverse events responsible for discontinuation were pul-
onary abnormalities including an increase in serum KL-6
evels. Only 1 patient was diagnosed with interstitial pneu-
onia. Although amiodarone-induced pulmonary toxicity is
ifﬁcult to prove, the main cause of the pulmonary injury
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Table 3 Clinical characteristics of patients with or without adverse effects.
With adverse effects (n = 24) Without adverse effects (n = 24) p value
Age (years) 68± 9 64± 10 N.S.
Male (%) 75 88 N.S.
Duration of AF (days) 1759± 3842 1196± 1689 N.S.
BNP (pg/ml) 493± 381 879± 778 0.036
NYHA class (II/III/IV) 18/5/1 18/6/0 N.S.
LVEF (%) 37± 7 33± 7 0.042
LVDd (mm) 59± 11 59± 11 N.S.
LAD (mm) 46± 10 46± 7 N.S.
Dose of amiodarone (mg) 160± 91 165± 70 N.S.
Follow-up duration (days) 457± 494 299± 263 N.S.
Medication
Beta-blockers (%) 54 67 N.S.
ACEi/ARB (%) 63 58 N.S.
Digitalis (%) 25 17 N.S.
Verapamil (%) 33 33 N.S.
Other antiarrhythmic agents (%) 9 17 N.S.
Statins (%) 17 21 N.S.
Hypertension (%) 67 63 N.S.
Diabetes mellitus (%) 38 38 N.S.
ACEi, angiotensin-converting enzyme inhibitor; AF, atrial ﬁbrillation; ARB, angiotensin II receptor blocker; BNP, B-type natriuretic peptide;
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was suspected to be hypersensitivity pneumonitis in that
patient. The median duration from the start of amiodarone
to the appearance of complications was 94 days (range
6—1751 days). Proarrhythmic effects were not seen in any
patients. There were no signiﬁcant differences in age, dose
of amiodarone, or other medication between the patients
with and without adverse effects (Table 3). Those with side
effects had signiﬁcantly lower BNP level and higher LVEF
compared with those without side effects.
Discussion
This study was a retrospective assessment of the efﬁcacy
and safety of oral amiodarone for the suppression of AF in
patients with CHF. Amiodarone was effective in 88%, 100%,
and 35% of the paroxysmal, persistent, and permanent AF
patients, respectively. In non-paroxysmal AF patients, oral
administration of amiodarone maintained SR after direct-
current shocks in 71% after 216 days and was associated with
a spontaneous cardioversion rate of 33% after 151 days. The
amiodarone-effective group had signiﬁcantly smaller left
atrium and ventricle than the ineffective group. Restora-
tion and maintenance of SR signiﬁcantly improved LVEF and
decreased BNP. The patients with LVEF ≤30% beneﬁted from
amiodarone comparably to those with LVEF >30%. Adverse
effects arose in 50% patients, resulting in discontinuation of
amiodarone in about half of them.
Management of patients with non-paroxysmal
AF and CHFAmiodarione is currently the most effective prophylactic
drug for the maintenance of SR in patients with AF who
undergo cardioversion. There are various reports on the
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nr; LVEF, left ventricular ejection fraction; NYHA, New York Heart
fﬁcacy of amiodarone in maintaining SR after cardiover-
ion and on spontaneous cardioversion rates in patients
ith non-paroxysmal AF. In the literature, the prevention of
ecurrence of AF after cardioversion ranges from 44% to 67%
fter follow-up of 8 weeks to 3 years [4—12]. In patients not
eceiving cardioversion, administration of oral amiodarone
s associated with a conversion rate between 12% and 83%
ver 28 days [6—11,13—15]. Conﬂicting results among trials
robably reﬂect differences in dosing and loading protocols
n trials, differing duration of AF prior to treatment, and
ollow-up periods.
The signiﬁcance of various factors in predicting AF free
nterval in chronic AF and CHF patients after electrical
ardioversion varies among previous reports [16]. In the
resent study, predictive factors for both preservation of SR
fter cardioversion and spontaneous conversion were left
trial and ventricular size. Clinical parameters such as age,
ender, duration of AF, and underlying cardiac disease did
ot affect the outcome. Amiodarone was less effective in
F patients with advanced anatomical remodeling in our
tudy.
AF is highly common in CHF patients and its incidence
ncreases with advancing CHF. On the other hand, AF with
n uncontrolled rapid and irregular ventricular response may
ggravate CHF. Na channel blockers in patients with AF in the
etting of CHF are associated with an increased risk of poten-
ially fatal proarrhythmia or aggravation of CHF caused by
egative inotropic effects [19], while amiodarone is recom-
ended in such patients because of its lower proarrhythmic
otential and lack of signiﬁcant negative inotropic effect in
HF [3]. According to previous reports, spontaneous conver-
ion to SR due to amiodarone in permanent AF with CHF was
een in 31% of patients after 4 years [17]. The mean mainte-
ance dose of amiodarone in our study was lower compared
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o that in this study. The presence of systolic LV dysfunc-
ion did not signiﬁcantly affect the outcome, indicating the
tility of amiodarone for controlling AF in patients with CHF.
linical advantage of successful rhythm
ontrol of AF
n patients with AF, the restoration and maintenance of
R is a desirable goal. AFFIRM demonstrated no signiﬁ-
ant differences in incidence of stroke, quality of life, or
ortality with rhythm vs. rate control [20]. In the AF-
HF study there was no difference in cardiovascular death
etween the rate control and rhythm control groups in the
atients with AF and CHF [21]. However, amiodarone can
mprove cardiac function and relieve symptoms by preven-
ion of AF recurrence [22]. In the current report, signiﬁcant
mprovement in LVEF and BNP levels was observed in the
ffective patients, although no signiﬁcant reverse remod-
ling occurred as assessed by LA and LV dimensions. We
ypothesize that the improvement in LVEF and BNP may have
een due in part to reversal of tachycardia-induced car-
iomyopathy by rate control due to other concomitant drugs
nd rhythm control by amiodarone. The lack of improvement
n LA and LV dimensions may have been due to irreversible
tructural changes. On the other hand, in the ineffective
roup no changes were observed in the mean of LVEF or BNP
evels during the follow-up. However, there was a minority
hose LVEF and BNP levels were improved. Oral amiodarone
ailed in rhythm control although its effects on rate control
ould cause such results in those patients [3].
dverse effects
ll antiarrhythmic agents have the potential for serious
dverse events, which are seen more commonly in patients
ith left ventricular dysfunction, CHF, or ischemic heart
isease [23,24]. The proportion of patients who discontin-
ed taking amiodarone because of adverse events in our
tudy (23%) was similar to that reported in other large trials
17,22] and a report from Japan [18]. In our series, amio-
arone was prescribed prudently with frequent check-ups
nd discontinued immediately if any suspicion of side effects
ppeared. We also attempted to switch amiodarone to less
oxic antiarrhythmic drugs if LV function improved. There-
ore, although the proportion of side effects was quite high,
here were no serious events. In this report patients with
dverse effects had better LVEF compared with those with-
ut adverse effects. It may be one of the causes that we
ollowed the patients with more impaired LV function more
arefully. We concluded that amiodarone was generally well
olerated when used with caution.
Amiodarone was usually started with the recommended
oading dose of 400mg, and reduced to the maintenance
ose of 50—200mg in individual patients. Both the loading
nd maintenance doses were adjusted due to patients’ age,
eart rate, body weight, the clinical states, and so on. In this
eport the mean dose of amiodarone was the last dose which
he patient was given. Some patients discontinued taking
miodarone because of adverse events during the loadingM. Kawabata et al.
eriod with the dose of 400mg, which made the mean dose
igher than other Japanese report [18].
imitations
ecause this was a retrospective study, it had some limi-
ations. There was no deﬁnite protocol and management
ecisions were made by individual physicians. Therefore,
he dose of amiodarone, the indication for cardioversion,
he method of dealing with adverse effects, and use of other
rugs were not uniform. The treatment was adjusted within
he limits of clinical judgment and patient tolerance. Thus,
ur results likely reﬂect what most experienced physicians
ould do in clinical practice. Prospective studies in a large
umber of patients with AF and CHF in Japan are needed to
valuate the therapeutic value of amiodarone.
It has been demonstrated that BNP and proBNP lev-
ls can facilitate diagnosis and guide CHF therapy [25].
n this report we deﬁned CHF patients as those whose
NP was higher than 100 pg/ml. While some researchers
tate values of >100 pg/ml indicate CHF, others suggest a
alue of >200 pg/ml. On the other hand, there are some
onditions other than CHF associated with elevated BNP
evels, including LV hypertrophy, tachycardia, right ven-
ricular overload, myocardial ischaemia, hypoxaemia, renal
ysfunction, advanced age, liver cirrhosis, sepsis, and infec-
ion [26]. In some patients BNP might be elevated because
f rapid ventricular response during AF.
The maintenance of SR after cardioversion or rever-
ion to SR may not be solely attributable to antiarrhythmic
roperties of amiodarone. Improvement of CHF and the
ffects of up-stream treatment by angiotensin-converting
nzyme inhibitors and angiotensin II receptor blockers would
lso support SR maintenance [27]. It is hard to distinguish
etween amiodarone effect and other factors.
Finally, the median follow-up duration of 265 days was
ot so long.
onclusion
ral amiodarone had clinical value in restoration and
aintenance of SR in CHF patients with paroxysmal and
ersistent AF. The successful rhythm control resulted in
he improvement of LVEF and the decrease in BNP levels.
owever, its utility appeared to be limited in those with
dvanced atrial anatomical remodeling of patients with CHF.
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